(ACOR) Acorda Therapeutics – Bull of the Day

November 8th, 2009

Acorda Therapeutics (ACOR) is one of the more interesting biotechnology
companies under our coverage. The company’s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010.

Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. Plus, the company is extremely well-capitalized with over $290 million in cash, and management has commercial experience with current approved product Zanaflex.

These are among the best fundamentals in all of biotech. We reiterate our Outperform rating on the stock.

Zacks Investment Research
View original at: Zacks.com News Feed


Similar Posts: | | Biotechnology | Healthcare

RSS feeds: ACOR | Acorda Therapeutics Inc | Biotechnology | Healthcare |

Other Posts by vitalstocks | RSS Feed for this author

Post a Response

You must be logged in to post a comment.